

From: [PETERSON Jenn L](#)
To: [Eric Blischke/R10/USEPA/US@EPA](#); [Joe Goulet/R10/USEPA/US@EPA](#)
Subject: RE: TZW Meeting Agenda
Date: 10/04/2006 04:20 PM

O.k., this is your meeting, so I don't really want to mess with the agenda. But, I did anyway. Note: I deleted or changed the order of some of your items. Use what you want...

-----Original Message-----

From: Blischke.Eric@epamail.epa.gov [<mailto:Blischke.Eric@epamail.epa.gov>]
Sent: Tuesday, October 03, 2006 3:47 PM
To: Goulet.Joe@epamail.epa.gov; PETERSON Jenn L
Subject: TZW Meeting Agenda

I have to run. Wanted to spend more time but got caught up in Lamprey discussions. Add any detail or missing items as you feel appropriate.

Eric

TZW Meeting Agenda

Risk Framework for TZW - Meeting Goal: To reach agreement on the risk framework to be used to evaluate TZW data in the Comprehensive Round 2 Site Summary and Data Gaps Report.

Problem Formulation and Conceptual Site Model:

Review HHRA and ERA CSM - Confirm understanding of receptors for which TZW is a complete pathway

TZW Screening Step:

Data Usability: Reach agreement on what data should be used in the risk screening process. For example, dissolved versus total, small and large volume peeper and trident, pilot data versus Round 2, etc.

Discuss TZW screening process. [it would be good to confirm that screening will take place for all contaminants detected]. Reach agreement on screening levels. PRGs versus risk screening? [confirm that the data will be presented the same for both]

Discuss how screening will be performed (e.g., point by point estimate).

TZW Screening Step Outcome - Discuss outcome of TZW screening process. Consider the following:

- HHRA - Direct
- ERA - Direct
- HHRA - Indirect
- ERA - Indirect

Discuss how data gaps will be identified based on screening step.

Confidence in screening value

Discuss the need for additional data collection in order to refine risk estimates from

exposure to TZ water. Circumstances where empirical testing may be needed in addition to screening, such as in-situ- bioassays or bioaccumulation testing.

Data and Risk Evaluation Presentation in Round Report related to risk characterization of TZ water

Discuss TZW in context of ERA LOE for receptors of interest (i.e., one LOE that must be considered in conjunction with other LOE). [it is my expectation that this step will occur after a full screening of TZ water is presented]. [Confirm that one line of evidence will not take priority; both will be presented].

Scientific / Management Decision Point: Consideration of multiple lines of evidence to determine there is adequate information to conclude that ecological risks are negligible or identify the need for remediation. Alternatively, one could conclude that the information is currently not adequate or that a more thorough assessment is needed to further characterize ecological effects. Multiple lines of evidence in the risk assessment could be used (bulk sediment toxicity testing, tissue concentrations, TZ water assessment) in this assessment, in addition to characterization data (e.g. additional characterization of plume migrate to better define contribution from upland sources and sediment). [We could discuss some of the management decisions that could be made after this analysis, or we could save for another meeting. *At any case, this should be discussed last.*]